HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Aluminum Hydroxide (Algeldrate)

Subscribe to New Research on Aluminum Hydroxide

A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.

Also Known As:

Algeldrate; Amphojel; Aldrox; Alhydrogel; Alugel; Aluminum Hydroxide (Gel), Dried; Atlas Brand of Algeldrate; Axcan Brand of Algeldrate; Basalgel; Brasivil; Chefaro Brand of Algeldrate; Dialume; Nephrox; Pepsamer; Rhône-Poulenc Rorer Brand of Algeldrate; Rocgel; Roques Brand of Algeldrate; Sanofi Winthrop Brand of Algeldrate; SmithKline Beecham Brand of Algeldrate; Stiefel Brand of Algeldrate; Whitehall Brand of Algeldrate; Wyeth Brand of Algeldrate; Algeldrate Atlas Brand; Algeldrate Axcan Brand; Algeldrate Chefaro Brand; Algeldrate Roques Brand; Algeldrate Stiefel Brand; Algeldrate Whitehall Brand; Algeldrate Wyeth Brand; Alumina, Hydrated; Gel, Aluminum Hydroxide; Hydroxide, Aluminum; Rhône Poulenc Rorer Brand of Algeldrate; Aluminum Hydroxide Gel; Hydrated Alumina; Aluminum hydroxide (Al(OH)3)

Networked: 367 relevant articles (25 outcomes, 35 trials/studies)

Relationship Network

Drug Context: Research Results

Inorganic Chemicals: 9

Experts

1.	Ellis, Ruth D: 8 articles (12/2014 - 01/2008)
2.	Miura, Kazutoyo: 7 articles (12/2014 - 01/2008)
3.	Fay, Michael P: 6 articles (01/2011 - 01/2008)
4.	Miller, Louis H: 6 articles (01/2010 - 01/2008)
5.	Mullen, Gregory E D: 6 articles (01/2010 - 03/2006)
6.	Long, Carole A: 5 articles (12/2014 - 03/2006)
7.	Martin, Laura B: 5 articles (01/2010 - 05/2009)
8.	Saul, Allan: 5 articles (10/2009 - 03/2006)
9.	Zhu, Daming: 4 articles (12/2014 - 01/2008)
10.	Dicko, Alassane: 4 articles (01/2011 - 12/2008)

Related Diseases

1.	Anthrax 01/01/2001 - "These recommendations concern the use of aluminum hydroxide adsorbed cell-free anthrax vaccine (Anthrax Vaccine Adsorbed [AVA], BioPort Corporation, Lansing, MI) in the United States for protection against disease caused by Bacillus anthracis. " 12/15/2000 - "These recommendations concern the use of aluminum hydroxide adsorbed cell-free anthrax vaccine (Anthrax Vaccine Adsorbed [AVA], BioPort Corporation, Lansing, MI) in the United States for protection against disease caused by Bacillus anthracis. " 05/31/2002 - "Anthrax vaccine, adsorbed (AVA) is a vaccine containing aluminum hydroxide that is administered as six subcutaneous (s.q.) doses over 18 months. " 08/14/2006 - "Hundred healthy volunteers were randomized in a 4:1 ratio to receive intramuscular doses of rPA102 in the following formulations: 5, 25, 50, or 75 microg of rPA102 in 82.5 microg aluminum hydroxide adjuvant at 0, 4, and 8 weeks; or the US licensed Anthrax Vaccine Adsorbed (AVA) at weeks 0 and 4. Local reactogenicity (mostly pain) was more common with AVA than with rPA102 following the first (94.7% versus 44.4%; p < 0.001) and the second (84.2% versus 35.4%; p < 0.001) vaccinations. " 04/02/2012 - "Advancements toward an improved vaccine against Bacillus anthracis, the causative agent of anthrax, have focused on formulations composed of the protective antigen (PA) adsorbed to aluminum hydroxide. "
2.	Malaria 01/01/2013 - "Previous clinical trials indicated the protective efficacy of BK-SE36 malaria vaccine that is constituted of SE36 recombinant protein and aluminum hydroxide gel. " 01/01/2011 - "A Phase 1-2b study of the blood stage malaria vaccine AMA1-C1/Alhydrogel was conducted in 336 children in Donéguébougou and Bancoumana, Mali. " 05/18/2009 - "A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali." 04/12/2011 - "GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. " 02/01/2002 - "Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model."
3.	Human Influenza (Influenza) 12/01/2011 - "Effect of aluminum hydroxide adjuvant on the immunogenicity of the 2009 pandemic influenza A/H1N1 vaccine: multi-level modeling of data with repeated measures." 11/05/2009 - "Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults." 08/13/2009 - "Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults." 11/01/2008 - "Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial." 10/01/1996 - "A challenge study was conducted to evaluate the safety and efficacy of an inactivated influenza H3N2 virus vaccine combined with Quil A/Alhydrogel mixture under controlled conditions in piglets. "
4.	Infection 02/10/2011 - "Aluminum hydroxide-ginseng extract and inactivated tachyzoites reduced the number of parasites circulating in the blood during acute phase but failed to limit the establishment of chronic infection. " 05/01/2010 - "Pretreatment with aluminum hydroxide before pathogen challenge reduced the development of Ralstonia solanacearum infection and decreased the extent of leaf injury. " 12/01/2009 - "We sought to define protective mechanisms of immunity to Staphylococcus aureus and Candida albicans bloodstream infections in mice immunized with the recombinant N-terminus of Als3p (rAls3p-N) vaccine plus aluminum hydroxide (Al(OH(3)) adjuvant, or adjuvant controls. " 01/07/2009 - "These observations demonstrate that baculovirus-produced rWNV-E can be formulated with aluminum hydroxide to produce a stable and safe vaccine which induces humoral immunity that can protect against WNV infection." 06/10/2005 - "This recombinant form of E protein, combined with aluminum hydroxide, is a candidate vaccine that may protect humans and horses against WN virus infections."
5.	Hyperphosphatemia 08/01/2005 - "Effectiveness of aluminum hydroxide timing administration in relation to meals in controlling hyperphosphatemia in dialysis patients." 05/01/1986 - "An infant with uremia due to congenital renal hypoplasia was treated with oral aluminum hydroxide for 9 months in an attempt to reduce hyperphosphatemia. " 05/03/1972 - "[Aluminum hydroxide treatment of hyperphosphatemia in uremia]." 08/01/2006 - "Treatment of hyperphosphatemia reduces dietary phosphate intake and includes phosphate binders such as aluminum hydroxide and aluminum carbonate. " 08/01/1995 - "Aluminum hydroxide and calcium compounds are used currently as phosphate-binding agents to treat hyperphosphatemia, but these compounds can cause undesirable side effects. "

Related Drugs and Biologics

1.	Antigens
2.	aluminum sulfate (alum)
3.	Magnesium Hydroxide (Brucite)
4.	Aluminum Hydroxide (Algeldrate)
5.	Calcium Carbonate (Limestone)
6.	Ovalbumin
7.	Gels
8.	hydroxide ion
9.	Merozoite Surface Protein 1 (MSA1)
10.	Cytokines

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Injections
3.	Low-Level Laser Therapy (LLLT)
4.	Radiotherapy
5.	Drug Therapy (Chemotherapy)